Data to inform elimination in Africa

Use of Data to Inform Planning and Financing Hepatitis Elimination in
Africa.

DURATION   18 months
STARTING DATE   1st September 2020
GEOGRAPHIC REACH   Africa
PARTNER     Center for Disease  Analysis Foundation, Inc. CDAF

 



AIM

To increase domestic and international investments for hepatitis elimination in Africa by providing up-to-date data and analysis on HBV/HCV prevalence, burden, mortality, diagnosis rate and treatment rate by collaborating with country-stakeholders and show the potential impact of action and inaction in order to drive political-will and decision-making at
the national and regional (African continent) level.

CONTEXT
The lack of data, conflicting data, underestimation of magnitude of hepatitis burden, the impact of action and no action, and fear of cost of elimination program prevent countries and international agencies from taking a stand on viral hepatitis elimination.

CDAF will use data and advanced decision support analytics to help policy makers understand the national burden, the value and cost of hepatitis elimination.

ACTION

• Assess hepatitis B & C burden, morbidity and mortality in Africa.

• Provide analytical support to 10 African countries to assess hepatitis B & C burden and the corresponding economic impact if countries did nothing or if they eliminated HBV/HCV.

• The results will be used to update/build an HCV and HBV model for every country in Africa with available data. The remaining countries’ data will be extrapolated to estimate HBV/ HCV prevalence, cirrhosis, liver cancer, mortality, diagnosis rate and treatment rate for the African continent.

EXPECTED RESULTS
• An updated understanding of HBV and HCV burden in African countries accounting for most of the hepatitis burden.

• A national report that uses available data and modelling to outline the current HBV and HCV burden and the requirements to meet the WHO elimination targets in each of the 10 countries.

• An economic impact & financing analysis to show the cost of different financing strategies (self-funding, patient co-pay, catalytic funding, etc.) and investment cases for national hepatitis elimination programs that can be used in discussions with Ministries of Finance or development banks.

• Results will be published by Polaris Observatory
https://cdafound.org/dashboard/polaris/dashboard.html

CATALYTIC IMPACT
The project hopes to accelerate the financing of national elimination plans in Africa by providing data to support funding decisions. CDAF will quantify the burden of viral hepatitis for national governments, quantify the budget impact and the economic and societal impact of HBV/HCV elimination.

In addition, CDAF will share its approach, successes, challenges, and lessons learned among a global audience of viral hepatitis policy makers, advocates, investors, implementers and others.

Read about our other grants.